Crystaline forms of HCV inhibitor

US9469673B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Ahmad Y. Sheikh · Lake Forest, US
• Moiz Diwan · Gurnee, US
• Agnes E. Pal · Grayslake, US
• Yuchuan Gong · Waukegan, US
• Paul J. Brackemeyer · Mount Prospect, US
• Geoff G. Zhang · Vernon Hills, US
• Seble H. Wagaw · Lake Bluff, US

Key dates

• Filing date: Jul 11, 2013
• Grant date: Oct 18, 2016
• Expiry date: Jul 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K5/0804
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2θ) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.